Author

Peter F. Bross

Observed names: P F Bross, Peter Bross, Peter F Bross

Institutions: Center for Biologics Evaluation and Research, United States Food and Drug Administration

Observed institutions: Center for Biologics Evaluation and Research, United States Food and Drug Administration, Center for Drug Evaluation and Research, George Washington University

ORCID: 0009-0003-0131-9021

Observed ORCID: 0009-0003-0131-9021

OpenAlex ID: A5091306873

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

2001 · P F Bross, J Beitz, et al. · PubMed · 856

Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

2003 · Robert C. Kane, Peter F. Bross, et al. · The Oncologist · 628

PDF

Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma

2004 · Peter F. Bross, Robert Kane, et al. · Clinical Cancer Research · 343

PDF

Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.

2003 · John R Johnson, Peter Bross, et al. · PubMed · 101

FDA Drug Approval Summaries: Fulvestrant

2002 · Peter F. Bross, Martin H. Cohen, et al. · The Oncologist · 90

PDF

Fulvestrant in postmenopausal women with advanced breast cancer.

2003 · Peter F Bross, Amy Baird, et al. · PubMed · 52

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer

2021 · Andrew DJ. Pearson, Claudia Rossig, et al. · European Journal of Cancer · 39

PDF

Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation

2013 · Ramjay S Vatsan, Peter F Bross, et al. · Journal for ImmunoTherapy of Cancer · 29

PDF

FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette–Guérin–Unresponsive Non–Muscle-Invasive Bladder Cancer

2024 · Laronna Colbert, Yuxia Jia, et al. · Clinical Cancer Research · 28

FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti–PD-1–Based Immunotherapy

2025 · Lianne Hu, Chaohong Fan, et al. · Clinical Cancer Research · 26

Drug–Diagnostic Codevelopment Strategies: FDA and Industry Dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop

2008 · Lois Hinman, Brian Spear, et al. · Pharmacogenomics · 17

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer

2023 · Elaine Chang, Noah M. Hahn, et al. · Bladder Cancer · 8

PDF

Regulation of biologic oncology products in the FDA׳s Center for Biologics Evaluation and Research

2014 · Peter F. Bross, Chaohong Fan, et al. · Urologic Oncology Seminars and Original Investigations · 7

Empiric antimicrobial therapy of febrile neutropenic patients undergoing haematopoietic stem cell transplantation

1999 · Bassema A Antabli, Peter Bross, et al. · International Journal of Antimicrobial Agents · 6

Report from the FDA Approval Summary: Imatinib Mesylate Capsules for Treatment of Adult Patients with Newly Diagnosed Philadelphia Chromosome- positive Chronic Myelogenous Leukemia in Chronic Phase

2003 · John R. Johnson, Peter Bross, et al. · 2

Expanded access for cancer patients: The 5-year FDA CBER experience.

2019 · Laronna S. Colbert, Peter F. Bross, et al. · Journal of Clinical Oncology · 1

Report from the FDA Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma

2004 · Peter Bross, Robert C. Kane, et al.

Works count: 17

Citation count: 2,233

H-index: 11

I10-index: 11